<DOC>
	<DOCNO>NCT00352339</DOCNO>
	<brief_summary>Switching Risperidone Aripiprazole early stage pharmacotherapy demonstrate efficacy compare risperidone continuation treatment treatment schizophrenia .</brief_summary>
	<brief_title>The New Strategy Pharmacological Treatment People With Schizophrenia</brief_title>
	<detailed_description>It think D2 Blocking agent necessary acute well maintenance phase pharmacological treatment patient schizophrenia . However , classical strategy produce long term adverse event drug TD , osteoporosis metabolic syndrome . To overcome adverse event , new strategy pharmacological treatment need .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Schizophrenia , DSMIV Acute phase Refractory Schizophrenia Substance Abuse High risk suicide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Switching</keyword>
	<keyword>Early stage</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Aripirazole</keyword>
</DOC>